<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?properties manuscript?><front><journal-meta><journal-id journal-id-type="nlm-journal-id">101738710</journal-id><journal-id journal-id-type="pubmed-jr-id">48234</journal-id><journal-id journal-id-type="nlm-ta">Cancer Drug Resist</journal-id><journal-id journal-id-type="iso-abbrev">Cancer Drug Resist</journal-id><journal-title-group><journal-title>Cancer drug resistance (Alhambra, Calif.)</journal-title></journal-title-group><issn pub-type="epub">2578-532X</issn></journal-meta><article-meta><article-id pub-id-type="pmid">31930190</article-id><article-id pub-id-type="pmc">6953902</article-id><article-id pub-id-type="doi">10.20517/cdr.2019.95</article-id><article-id pub-id-type="manuscript">NIHMS1063588</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Entrapment of DNA topoisomerase-DNA complexes by nucleotide/nucleoside analogs</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Gmeiner</surname><given-names>William H.</given-names></name></contrib><aff id="A1">Department of Cancer Biology, Wake Forest School of Medicine, Winston-Salem, NC 27157, USA.</aff></contrib-group><author-notes><fn fn-type="con" id="FN1"><p id="P1">Authors&#x02019; contributions</p><p id="P2">The author contributed solely to the article.</p></fn><corresp id="CR1"><bold>Correspondence to</bold>: Prof. William H. Gmeiner, Department of Cancer Biology, Wake Forest School of Medicine, Winston-Salem, NC 27157, USA. <email>bgmeiner@wakehealth.edu</email></corresp></author-notes><pub-date pub-type="nihms-submitted"><day>15</day><month>12</month><year>2019</year></pub-date><pub-date pub-type="epub"><day>19</day><month>12</month><year>2019</year></pub-date><pub-date pub-type="ppub"><year>2019</year></pub-date><pub-date pub-type="pmc-release"><day>10</day><month>1</month><year>2020</year></pub-date><volume>2</volume><fpage>994</fpage><lpage>1001</lpage><!--elocation-id from pubmed: 10.20517/cdr.2019.95--><permissions><license license-type="open-access"><license-p>This article is licensed under a Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, sharing, adaptation, distribution and reproduction in any medium or format, for any purpose, even commercially, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.</license-p></license></permissions><self-uri xlink:href="https://cdrjournal.com/article/view/3282"/><abstract id="ABS1"><p id="P3">Topoisomerases are well-validated targets for cancer chemotherapy and DNA topoisomerase 1 (Top1) is the sole target of the camptothecin (CPT) class of anticancer drugs. Over the last 20 years, multiple studies have shown Top1 activity is modulated by non-native DNA structures and this can lead to trapping of Top1 cleavage complexes (Top1cc) and conversion to DNA double strand breaks. Among the perturbations to DNA structure that generate Top1cc are nucleoside analogs that are incorporated into genomic DNA during replication including cytarabine, gemcitabine, and 5-fluoro-2&#x02032;-deoxyuridine (FdU). We review the literature summarizing the role of Top1cc in mediating the DNA damaging and cytotoxic activities of nucleoside analogs. We also summarize studies demonstrating distinct differences between Top1cc induced by nucleoside analogs and CPTs, particularly with regard to DNA repair. Collectively, these studies demonstrate that, while Top1 is a common target for both Top1 poisons such as CPT and nucleoside analogs such as FdU, these agents are not redundant. In recent years, studies have shown that Top1 poisons and nucleoside analogs together with other anti-cancer drugs such as cisplatin cause replication stress and the DNA repair pathways that modulate the cytotoxic activities of these compounds are being elucidated. We present an overview of this evolving literature, which has implications for how targeting of Top1 with nucleoside analogs can be used more effectively for cancer treatment.</p></abstract><kwd-group><kwd>DNA topoisomerase 1</kwd><kwd>cancer chemotherapy</kwd><kwd>cytarabine</kwd><kwd>gemcitabine</kwd><kwd>fluoropyrimidine</kwd></kwd-group></article-meta></front><body><sec id="S1"><title>INTRODUCTION</title><p id="P4">Targeting DNA is one of the all-time most successful strategies for cancer treatment. Radiation and DNA damaging drugs such as cyclophosphamide have remained among the most widely used therapeutic modalities for cancer treatment for decades. A major advance for targeting DNA for cancer treatment was the discovery that camptothecin (CPT), a natural product identified by Wall and Wani<sup>[<xref rid="R1" ref-type="bibr">1</xref>]</sup> in a screen for natural products with anti-cancer activity, targeted DNA topoisomerase 1 (Top1)<sup>[<xref rid="R2" ref-type="bibr">2</xref>]</sup>. In human cells, Top1, a TypeIB topoisomerase<sup>[<xref rid="R3" ref-type="bibr">3</xref>]</sup>, relieves superhelical density generated during replication<sup>[<xref rid="R4" ref-type="bibr">4</xref>]</sup> and transcription<sup>[<xref rid="R5" ref-type="bibr">5</xref>]</sup> by nicking supercoiled DNA to allow for spontaneous relaxation of supercoils (i.e., &#x0201c;controlled rotation&#x0201d;<sup>[<xref rid="R6" ref-type="bibr">6</xref>]</sup>), and then re-ligating the relaxed DNA. CPT analogs stabilize the nicked DNA with Top1 covalently bound in a ternary cleavage complex (Top1cc) that consists of Top1, DNA, and CPT<sup>[<xref rid="R7" ref-type="bibr">7</xref>]</sup>. The resulting Top1cc is converted into a DNA double strand break (DSB) upon collision with either an advancing replication fork<sup>[<xref rid="R8" ref-type="bibr">8</xref>,<xref rid="R9" ref-type="bibr">9</xref>]</sup> or the transcriptional machinery<sup>[<xref rid="R10" ref-type="bibr">10</xref>,<xref rid="R11" ref-type="bibr">11</xref>]</sup>. Accumulation of unrepaired DNA DSBs stimulates activation of apoptosis.</p><p id="P5">With the realization that CPT analogs such as topotecan and Irinotecan (CPTs) displayed anti-cancer activity during clinical trials in the early 1990s<sup>[<xref rid="R12" ref-type="bibr">12</xref>]</sup>, there was growing appreciation that, in addition to its role as the sole target for CPTs, Top1 also mediated the cytotoxic effects of diverse treatments. These included generic DNA damage due to reactive oxygen species<sup>[<xref rid="R13" ref-type="bibr">13</xref>,<xref rid="R14" ref-type="bibr">14</xref>]</sup>, and nucleoside analogs<sup>[<xref rid="R15" ref-type="bibr">15</xref>]</sup> used for cancer treatment. Studies from the Pommier lab showed that perturbations to DNA structure could result in either increased susceptibility to Top1-mediated DNA damage, or cause Top1 to be refractory from accessing sites with certain types of DNA damage. For example, abasic sites that may occur spontaneously in genomic DNA or as intermediates during base excision repair were shown to cause position-specific changes in Top1 cleavage activity<sup>[<xref rid="R16" ref-type="bibr">16</xref>]</sup>. Abasic sites within the first four bases 5&#x02019; to the Top1 cleavage site suppressed Top1 cleavage at the preferred site, but stimulated Top1 cleavage at alternative, nearby sites. However, an abasic site immediately 3&#x02019; to the Top1 cleavage site resulted in formation of a stable Top1cc even in the absence of CPT. Further studies showed that DNA with nicks or gaps with 5&#x02019;-phosphate termini that could be generated by ionizing radiation or by the processing of abasic sites also modulated Top1 activity<sup>[<xref rid="R17" ref-type="bibr">17</xref>]</sup>. Nicks upstream of a preferred Top1 site suppressed Top1 activity, but irreversible Top1cc formed if nicks were positioned opposite to the Top1 cleavage site in the non-scissile strand. Top1 trapping was also detected at base mismatches<sup>[<xref rid="R16" ref-type="bibr">16</xref>,<xref rid="R18" ref-type="bibr">18</xref>]</sup>. These findings implicated Top1 in modulating repair of damaged DNA and indicated Top1cc could be intermediates leading to DNA DSBs induced by diverse treatments and conditions not previously realized to target Top1. Further studies investigated 8OxoG<sup>[<xref rid="R13" ref-type="bibr">13</xref>]</sup>, benzo[<italic>a</italic>]pyrene diol epoxide adducts<sup>[<xref rid="R19" ref-type="bibr">19</xref>]</sup>, and other types of damage<sup>[<xref rid="R20" ref-type="bibr">20</xref>]</sup>, and demonstrated these either trapped Top1 or inhibited Top1 cleavage, in a position-dependent manner. The paradoxical position-dependent enhancement/inhibition effects of damaged bases on Top1 activity were investigated using X-ray structural analysis. These studies revealed Top1 binds DNA in an inactive conformation and rearrangement of the active site is required for catalysis. It was found that 8-OxoG at the +1 position of the scissile strand stabilized the inactive, DNA-bound state<sup>[<xref rid="R21" ref-type="bibr">21</xref>]</sup>.</p></sec><sec id="S2"><title>POISONING OF TOP1 WITH NUCLEOSIDE ANALOGS</title><p id="P6">Nucleoside analogs such as cytarabine (AraC) are among the most active anti-cancer drugs<sup>[<xref rid="R22" ref-type="bibr">22</xref>]</sup>, and are used to treat diverse malignancies including front-line treatment for acute myeloid leukemia. AraC is phosphorylated [by deoxycytidine kinase (dCK)], and AraCTP (AraC 5&#x02019;-<italic>O</italic>-triphosphate) is incorporated into nascent DNA during replication, which alters DNA conformation<sup>[<xref rid="R23" ref-type="bibr">23</xref>]</sup> and stability<sup>[<xref rid="R24" ref-type="bibr">24</xref>]</sup> and inhibits strand elongation. AraC thus serves as a chain-terminating nucleoside analog<sup>[<xref rid="R25" ref-type="bibr">25</xref>]</sup>. Studies with the same model system derived from Tetrahymena hexadecameric rDNA sequence described by Westergaard and co-workers<sup>[<xref rid="R26" ref-type="bibr">26</xref>]</sup> were used to study the effects of DNA damage on Top1 activity [<xref rid="F1" ref-type="fig">Figure 1</xref>]. These studies revealed that AraC at the +1 position relative to the Top1 cleavage site enhanced Top1cc formation 4-6- fold by inhibiting the re-ligation step of Top1 catalysis<sup>[<xref rid="R27" ref-type="bibr">27</xref>]</sup>. AraC substitution at the scissile and non-scissile strands had similar effects on Top1cc enhancement [<xref rid="T1" ref-type="table">Table 1</xref>]. The biological relevance of Ara-Cinduced Top1cc was demonstrated using CPT-resistant murine leukemia cells which were 7&#x02013;10-fold more resistant to AraC than parental cells, but equally sensitive to alkylating agents, Top2 inhibitors, and tubulin poisons. The levels of Top1cc formed in AraC-treated cells were lower than those due to CPT treatment, likely because AraC&#x02019;s chain termination property self-limits its incorporation into DNA. This may explain why recent immunodetection studies did not detect Top1cc in AraC-treated cells<sup>[<xref rid="R28" ref-type="bibr">28</xref>]</sup>. AraC incorporation into DNA also poisons Top2<sup>[<xref rid="R29" ref-type="bibr">29</xref>]</sup>. The DNA damage response activated by AraC is similar to Top1 and Top2 poisons and involves Rad9 binding and S-phase checkpoint activation<sup>[<xref rid="R30" ref-type="bibr">30</xref>]</sup>. DNA synthesis inhibitors including AraC display similar dependence as Top1 and Top2 poisons to multiple DNA repair genes including <italic>SLFN11</italic> and <italic>SLX4</italic><sup>[<xref rid="R31" ref-type="bibr">31</xref>]</sup>. SLFN11 was discovered in a bioinformatics analysis<sup>[<xref rid="R32" ref-type="bibr">32</xref>]</sup>, and is crucial for mediating the cytotoxicity of Top1 and Top2 poisons, including nucleoside analogs such as AraC that cause Top1-mediated DNA damage<sup>[<xref rid="R33" ref-type="bibr">33</xref>]</sup>. Interestingly, AraC blocking elongation of 3&#x02019;-termini is removed by tyrosyl DNA phosphodiesterase 1 (Tdp1), an enzyme that also cleaves the tyrosyl-DNA phosphodiester bond during Top1cc repair. Tdp1 also repairs DNA breaks induced by Sapacitabine, a nucleoside analog with structural similarities to AraC<sup>[<xref rid="R34" ref-type="bibr">34</xref>]</sup>.</p><p id="P7">Gemcitabine (GEM<sup>[<xref rid="R35" ref-type="bibr">35</xref>]</sup> or dFdC) is a deoxycytidine (dC) analog that is used for front-line treatment of pancreatic cancer and other malignancies. Structurally, gemcitabine differs from dC by inclusion of a geminal difluoro at C2&#x02019;. GEM is readily phosphorylated by dCK and the diphosphate (dFdCDP) inhibits ribonucleotide reductase, depleting cellular dCTP and potentiating dFdCTP incorporation into DNA. Upon incorporation of GEM into DNA, polymerase pausing occurs, but, unlike AraC, GEM is not primarily chain terminating and most GEM is present at internucleotide positions in genomic DNA<sup>[<xref rid="R36" ref-type="bibr">36</xref>]</sup>. GEM cytotoxicity strongly correlates with DNA incorporation. Gmeiner and co-workers showed that GEM inclusion in a model Okazaki fragment altered the electrostatic surface, which may affect protein binding<sup>[<xref rid="R37" ref-type="bibr">37</xref>,<xref rid="R38" ref-type="bibr">38</xref>]</sup>. Inclusion of GEM into two model Top1 substrates revealed position-specific effects on Top1cc formation<sup>[<xref rid="R39" ref-type="bibr">39</xref>]</sup>. GEM substitution at the +1 site increased Top1cc formation 5&#x02013;7-fold while GEM at the &#x02212;5 position of the non-scissile strand induced a new Top1 cleavage site adjacent to GEM substitution. GEM effects were site-specific and GEM at &#x02212;3 or +2 of the scissile strand had no effect on Top1cc formation. Similar to AraC, GEM inhibited the re-ligation step of Top1 catalysis and Top1-deficient P388 CPT-resistant murine leukemia cells were cross-resistant to GEM, consistent with the <italic>in vivo</italic> significance of Top1cc for anti-tumor activity.</p></sec><sec id="S3"><title>DUAL TARGETING OF THYMIDYLATE SYNTHASE/TOP1 WITH F10</title><p id="P8">Fluoropyrimidine drugs (FPs) are used to treat &#x0003e; 2 million cancer patients worldwide each year<sup>[<xref rid="R40" ref-type="bibr">40</xref>]</sup>. Although the deoxynucleotide metabolites FdUMP and FdUTP are primarily responsible for anti-cancer activity, FPs are administered either as the nucleobase (5-FU) or as 5-FU pro-drugs (e.g., capecitabine), because the deoxynucleoside FdU is very rapidly converted to 5-FU in the liver<sup>[<xref rid="R41" ref-type="bibr">41</xref>]</sup>. A principal target for FP chemotherapy is thymidylate synthase (TS)<sup>[<xref rid="R42" ref-type="bibr">42</xref>]</sup>, which is required for <italic>de novo</italic> thymidine (Thy) biosynthesis to support rapid proliferation of malignant cells. 5-FU is inefficiently converted to the TS inhibitory metabolite FdUMP with ~85% of the dose administered to humans degraded or excreted intact<sup>[<xref rid="R43" ref-type="bibr">43</xref>]</sup>. Among anabolic metabolites, ribonucleotides that contribute primarily to systemic toxicities are produced at higher levels than deoxynucleotides<sup>[<xref rid="R44" ref-type="bibr">44</xref>]</sup>. The Gmeiner lab developed FP polymers (e.g., F10) to efficiently generate FdUMP<sup>[<xref rid="R45" ref-type="bibr">45</xref>]</sup>. F10 displayed improved cytotoxicity relative to 5-FU in the NCI60 cell line panel<sup>[<xref rid="R46" ref-type="bibr">46</xref>,<xref rid="R47" ref-type="bibr">47</xref>]</sup>, is preferentially taken up by malignant cells<sup>[<xref rid="R48" ref-type="bibr">48</xref>]</sup>, and thus does not require extracellular degradation to monomers for biological activity.</p><p id="P9">Analysis of F10&#x02019;s mechanism based on the response profile across the NCI60 cell line screen using the COMPARE<sup>[<xref rid="R49" ref-type="bibr">49</xref>]</sup> algorithm revealed similarities to Top1 poisons<sup>[<xref rid="R46" ref-type="bibr">46</xref>,<xref rid="R47" ref-type="bibr">47</xref>]</sup>. In contrast, 5-FU was distantly related to both F10 and Top1 poisons. In collaboration with Pommier, we showed F10 induced Top1cc in malignant cells and that CPT-resistant cells were cross-resistant to F10 as well as to FdUMP, FdU, and raltitrexed (an anti-folate TS inhibitor)<sup>[<xref rid="R46" ref-type="bibr">46</xref>]</sup>. FdU mismatched base pairs in the non-scissile strand at positions +1 or +2 relative to a model Top1 cleavage site trapped Top1cc, and inhibited the re-ligation step of Top1 catalysis. These studies used the same model duplex used to study Top1cc by AraC and GEM [<xref rid="F1" ref-type="fig">Figure 1</xref>]. We went on to show that FdU-dG mismatched base pair destabilized duplex DNA, which may explain why FdU substitution in the non-scissile strand perturbed Top1-mediated re-ligation<sup>[<xref rid="R50" ref-type="bibr">50</xref>,<xref rid="R51" ref-type="bibr">51</xref>]</sup>. The cytotoxic effects of F10 require TS inhibition and are reversible with exogenous Thy; however, Thy reversibility is limited to &#x0003c; 16 h of treatment<sup>[<xref rid="R52" ref-type="bibr">52</xref>]</sup>, a time that corresponds to Top1cc formation, after which F10&#x02019;s cytotoxic effects are no longer reversible with Thy. Thus, Top1cc formation appears to be an irreversible step in F10&#x02019;s mechanism leading to cell death.</p><p id="P10">Top1cc induced by F10 differ fundamentally from CPT analogs because repair occurs under thymineless conditions, which renders repair ineffective since FdU or dU are re-incorporated at the lesion site [<xref rid="F2" ref-type="fig">Figure 2A</xref> and <xref rid="F2" ref-type="fig">B</xref>]. Using DT40 knockout (ko) cells deficient in Tdp1, PARP1, and other DNA repair enzymes, we showed that F10 and CPT displayed an opposite dependence on the expression of Tdp1<sup>[<xref rid="R53" ref-type="bibr">53</xref>]</sup> [<xref rid="F2" ref-type="fig">Figure 2C</xref>], an important Top1cc repair enzyme. While Tdp1-ko cells were hypersensitive to CPT, they were relatively resistant to higher concentrations of F10, which is consistent with Tdp1 contributing to F10 cytotoxicity. Results for PARP1-ko cells mirrored Tdp1, which is consistent with PARP1/Tdp1 epistasis for Top1cc repair<sup>[<xref rid="R54" ref-type="bibr">54</xref>]</sup>. A possible explanation for these differences is that Tdp1-mediated repair actually amplifies F10-induced Top1-mediated DNA damage by repeatedly regenerating the lesion [<xref rid="F2" ref-type="fig">Figure 2A</xref> and <xref rid="F2" ref-type="fig">B</xref>]. This dual targeting of TS/Top1 by F10 results in potent anti-tumor activity, which we have demonstrated occurs in multiple pre-clinical models of AML<sup>[<xref rid="R55" ref-type="bibr">55</xref>]</sup>, acute lymphocytic leukemia<sup>[<xref rid="R48" ref-type="bibr">48</xref>]</sup>, prostate cancer<sup>[<xref rid="R56" ref-type="bibr">56</xref>]</sup>, glioblastoma<sup>[<xref rid="R57" ref-type="bibr">57</xref>]</sup>, colorectal cancer, and pancreatic ductal adenocarcinoma.</p></sec><sec id="S4"><title>TOP1 POISONS AND REPLICATION STRESS</title><p id="P11">Nucleoside analogs and CPT derivatives both generate Top1cc and, while nucleoside analogs affect alternative targets (e.g., polymerase pausing and chain termination), collectively these agents are part of a larger class of drugs that exert anti-cancer activity primarily through replication stress<sup>[<xref rid="R31" ref-type="bibr">31</xref>]</sup>. Studies in recent years have begun to elucidate the molecular factors that generally affect cellular response to this class of agents. The goal of these studies is to identify which patients are likely to respond to therapy with these agents, and to identify new molecular targets that complement their Top1-directed activities. PARP and Tdp1 are both important for Top1cc repair and inhibitors of these enzymes are being evaluated in combination with Top1 poisons, with PARP inhibitors showing promising activity in this context in recent clinical studies<sup>[<xref rid="R58" ref-type="bibr">58</xref>]</sup>. Recent studies have identified SLFN11 as the major determinant in response to drugs that induce replication stress<sup>[<xref rid="R33" ref-type="bibr">33</xref>]</sup>. Malignant cells that downregulate SLFN11 through epigenetic silencing are relatively less sensitive to Top1 poisons and other agents that induce replication stress. Either agents that reverse epigenetic silencing or those that inhibit ATR, a kinase that functions in parallel with SLFN11 in repressing replication in cells treated with Top1 poisons, can sensitize cells with downregulated SLFN11 expression to the cytotoxic activities of Top1 poisons<sup>[<xref rid="R59" ref-type="bibr">59</xref>]</sup>. Efficacy of combination therapy regimens will depend on both malignancy-specific factors such as SLFN11 expression and drug-specific factors. In particular, the opposite dependence of F10 and CPT with regards to PARP/Tdp1-mediated repair indicates that different approaches may be required to enhance the activities of fluoropyrimidine polymers relative to CPT derivatives, or alternative nucleoside analogs. Top1-directed activities of nucleoside analogs contribute to their clinical activities. Comprehensive, mechanism-based combination therapy can enhance these activities, and further improve outcomes.</p></sec><sec id="S5"><title>CONCLUSION</title><p id="P12">Top1 poisons continue to be among the world&#x02019;s most important anti-cancer drugs. In addition to being the sole target for CPT derivatives, Top1 is an important target for agents that induce DNA damage including ionizing radiation, reactive oxygen species, or formation of covalent adducts. Top1 is also target for nucleoside analogs such as AraC and GEM. Dual targeting of TS/Top1 by DNA-directed fluoropyrimidines such as F10 shows promising activity in pre-clinical cancer models. TS/Top1 dual targeting is distinct from Top1 poisoning by CPT derivatives because Top1cc repair occurs under thymineless conditions and shows different dependence on Top1cc repair pathways. A challenge in coming years will be how to use the Top1 poisoning activity of nucleoside analogs for improved care in the context of personalized therapy taking into account patient-specific expression of DNA repair pathways.</p></sec></body><back><ack id="S6"><title>Financial support and sponsorship</title><p id="P13">Research reported in this publication was supported by the National Cancer Institute&#x02019;s Cancer Center Support Grant (P30CA012197) issued to the Wake Forest Baptist Comprehensive Cancer Center. Gmeiner WH is supported by NIH grant (NIH-NCI R21 CA218933).</p></ack><fn-group><fn id="FN3"><p id="P14">Availability of data and materials</p><p id="P15">Not applicable.</p></fn><fn fn-type="COI-statement" id="FN4"><p id="P16">Conflicts of interest</p><p id="P17">The author declared that there are no conflicts of interest.</p></fn><fn id="FN5"><p id="P18">Ethical approval and consent to participate</p><p id="P19">Not applicable.</p></fn><fn id="FN6"><p id="P20">Consent for publication</p><p id="P21">Not applicable.</p></fn></fn-group><ref-list><title>REFERENCES</title><ref id="R1"><label>1.</label><mixed-citation publication-type="journal"><name><surname>Wall</surname><given-names>ME</given-names></name>, <name><surname>Wani</surname><given-names>MC</given-names></name>. <article-title>Camptothecin. Discovery to clinic</article-title>. <source>Ann N Y Acad Sci</source>
<year>1996</year>;<volume>803</volume>:<fpage>1</fpage>&#x02013;<lpage>12</lpage>.</mixed-citation></ref><ref id="R2"><label>2.</label><mixed-citation publication-type="journal"><name><surname>Champoux</surname><given-names>JJ</given-names></name>. <article-title>Structure-based analysis of the effects of camptothecin on the activities of human topoisomerase I</article-title>. <source>Ann N Y Acad Sci</source>
<year>2000</year>;<volume>922</volume>:<fpage>56</fpage>&#x02013;<lpage>64</lpage>.<pub-id pub-id-type="pmid">11193925</pub-id></mixed-citation></ref><ref id="R3"><label>3.</label><mixed-citation publication-type="journal"><name><surname>Vos</surname><given-names>SM</given-names></name>, <name><surname>Tretter</surname><given-names>EM</given-names></name>, <name><surname>Schmidt</surname><given-names>BH</given-names></name>, <name><surname>Berger</surname><given-names>JM</given-names></name>. <article-title>All tangled up: how cells direct, manage and exploit topoisomerase function</article-title>. <source>Nat Rev Mol Cell Biol</source>
<year>2011</year>;<volume>12</volume>:<fpage>827</fpage>&#x02013;<lpage>41</lpage>.<pub-id pub-id-type="pmid">22108601</pub-id></mixed-citation></ref><ref id="R4"><label>4.</label><mixed-citation publication-type="journal"><name><surname>Peter</surname><given-names>BJ</given-names></name>, <name><surname>Ullsperger</surname><given-names>C</given-names></name>, <name><surname>Hiasa</surname><given-names>H</given-names></name>, <name><surname>Marians</surname><given-names>KJ</given-names></name>, <name><surname>Cozzarelli</surname><given-names>NR</given-names></name>. <article-title>The structure of supercoiled intermediates in DNA replication</article-title>. <source>Cell</source>
<year>1998</year>;<volume>94</volume>:<fpage>819</fpage>&#x02013;<lpage>27</lpage>.<pub-id pub-id-type="pmid">9753328</pub-id></mixed-citation></ref><ref id="R5"><label>5.</label><mixed-citation publication-type="journal"><name><surname>Liu</surname><given-names>LF</given-names></name>, <name><surname>Wang</surname><given-names>JC</given-names></name>. <article-title>Supercoiling of the DNA template during transcription</article-title>. <source>Proc Natl Acad Sci U S A</source>
<year>1987</year>;<volume>84</volume>:<fpage>7024</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="pmid">2823250</pub-id></mixed-citation></ref><ref id="R6"><label>6.</label><mixed-citation publication-type="journal"><name><surname>Stewart</surname><given-names>L</given-names></name>, <name><surname>Redinbo</surname><given-names>MR</given-names></name>, <name><surname>Qiu</surname><given-names>X</given-names></name>, <name><surname>Hol</surname><given-names>WG</given-names></name>, <name><surname>Champoux</surname><given-names>JJ</given-names></name>. <article-title>A model for the mechanism of human topoisomerase I</article-title>. <source>Science</source>
<year>1998</year>;<volume>279</volume>:<fpage>1534</fpage>&#x02013;<lpage>41</lpage>.<pub-id pub-id-type="pmid">9488652</pub-id></mixed-citation></ref><ref id="R7"><label>7.</label><mixed-citation publication-type="journal"><name><surname>Staker</surname><given-names>BL</given-names></name>, <name><surname>Hjerrild</surname><given-names>K</given-names></name>, <name><surname>Feese</surname><given-names>MD</given-names></name>, <name><surname>Behnke</surname><given-names>CA</given-names></name>, <name><surname>Burgin</surname><given-names>AB</given-names><suffix>Jr</suffix></name>, <etal/>
<article-title>The mechanism of topoisomerase I poisoning by a camptothecin analog</article-title>. <source>Proc Natl Acad Sci U S A</source>
<year>2002</year>;<volume>99</volume>:<fpage>15387</fpage>&#x02013;<lpage>92</lpage>.<pub-id pub-id-type="pmid">12426403</pub-id></mixed-citation></ref><ref id="R8"><label>8.</label><mixed-citation publication-type="journal"><name><surname>Lin</surname><given-names>CP</given-names></name>, <name><surname>Ban</surname><given-names>Y</given-names></name>, <name><surname>Lyu</surname><given-names>YL</given-names></name>, <name><surname>Liu</surname><given-names>LF</given-names></name>. <article-title>Proteasome-dependent processing of topoisomerase I-DNA adducts into DNA double strand breaks at arrested replication forks</article-title>. <source>J Biol Chem</source>
<year>2009</year>;<volume>284</volume>:<fpage>28084</fpage>&#x02013;<lpage>92</lpage>.<pub-id pub-id-type="pmid">19666469</pub-id></mixed-citation></ref><ref id="R9"><label>9.</label><mixed-citation publication-type="journal"><name><surname>Regairaz</surname><given-names>M</given-names></name>, <name><surname>Zhang</surname><given-names>YW</given-names></name>, <name><surname>Fu</surname><given-names>H</given-names></name>, <name><surname>Agama</surname><given-names>KK</given-names></name>, <name><surname>Tata</surname><given-names>N</given-names></name>, <etal/>
<article-title>Mus81-mediated DNA cleavage resolves replication forks stalled by topoisomerase I-DNA complexes</article-title>. <source>J Cell Biol</source>
<year>2011</year>;<volume>195</volume>:<fpage>739</fpage>&#x02013;<lpage>49</lpage>.<pub-id pub-id-type="pmid">22123861</pub-id></mixed-citation></ref><ref id="R10"><label>10.</label><mixed-citation publication-type="journal"><name><surname>Sordet</surname><given-names>O</given-names></name>, <name><surname>Redon</surname><given-names>CE</given-names></name>, <name><surname>Guirouilh-Barbat</surname><given-names>J</given-names></name>, <name><surname>Smith</surname><given-names>S</given-names></name>, <name><surname>Solier</surname><given-names>S</given-names></name>, <etal/>
<article-title>Ataxia telangiectasia mutated activation by transcription- and topoisomerase I-induced DNA double-strand breaks</article-title>. <source>EMBO Rep</source>
<year>2009</year>;<volume>10</volume>:<fpage>887</fpage>&#x02013;<lpage>93</lpage>.<pub-id pub-id-type="pmid">19557000</pub-id></mixed-citation></ref><ref id="R11"><label>11.</label><mixed-citation publication-type="journal"><name><surname>Cristini</surname><given-names>A</given-names></name>, <name><surname>Ricci</surname><given-names>G</given-names></name>, <name><surname>Britton</surname><given-names>S</given-names></name>, <name><surname>Salimbeni</surname><given-names>S</given-names></name>, <name><surname>Huang</surname><given-names>SN</given-names></name>, <etal/>
<article-title>Dual processing of R-loops and topoisomerase I induces transcription-dependent DNA double-strand breaks</article-title>. <source>Cell Rep</source>
<year>2019</year>;<volume>28</volume>:<fpage>3167</fpage>&#x02013;<lpage>81.e6</lpage>.<pub-id pub-id-type="pmid">31533039</pub-id></mixed-citation></ref><ref id="R12"><label>12.</label><mixed-citation publication-type="journal"><name><surname>Rowinsky</surname><given-names>EK</given-names></name>. <article-title>Weekly topotecan: an alternative to topotecan&#x02019;s standard daily &#x000d7; 5 schedule?</article-title>
<source>Oncologist</source>
<year>2002</year>;<volume>7</volume>:<fpage>324</fpage>&#x02013;<lpage>30</lpage>.<pub-id pub-id-type="pmid">12185294</pub-id></mixed-citation></ref><ref id="R13"><label>13.</label><mixed-citation publication-type="journal"><name><surname>Pourquier</surname><given-names>P</given-names></name>, <name><surname>Ueng</surname><given-names>LM</given-names></name>, <name><surname>Fertala</surname><given-names>J</given-names></name>, <name><surname>Wang</surname><given-names>D</given-names></name>, <name><surname>Park</surname><given-names>HJ</given-names></name>, <etal/>
<article-title>Induction of reversible complexes between eukaryotic DNA topoisomerase I and DNA-containing oxidative base damages. 7, 8-dihydro-8-oxoguanine and 5-hydroxycytosine</article-title>. <source>J Biol Chem</source>
<year>1999</year>;<volume>274</volume>:<fpage>8516</fpage>&#x02013;<lpage>23</lpage>.<pub-id pub-id-type="pmid">10085084</pub-id></mixed-citation></ref><ref id="R14"><label>14.</label><mixed-citation publication-type="journal"><name><surname>Daroui</surname><given-names>P</given-names></name>, <name><surname>Desai</surname><given-names>SD</given-names></name>, <name><surname>Li</surname><given-names>TK</given-names></name>, <name><surname>Liu</surname><given-names>AA</given-names></name>, <name><surname>Liu</surname><given-names>LF</given-names></name>. <article-title>Hydrogen peroxide induces topoisomerase I-mediated DNA damage and cell death</article-title>. <source>J Biol Chem</source>
<year>2004</year>;<volume>279</volume>:<fpage>14587</fpage>&#x02013;<lpage>94</lpage>.<pub-id pub-id-type="pmid">14688260</pub-id></mixed-citation></ref><ref id="R15"><label>15.</label><mixed-citation publication-type="journal"><name><surname>Pourquier</surname><given-names>P</given-names></name>, <name><surname>Jensen</surname><given-names>AD</given-names></name>, <name><surname>Gong</surname><given-names>SS</given-names></name>, <name><surname>Pommier</surname><given-names>Y</given-names></name>, <name><surname>Rogler</surname><given-names>CE</given-names></name>. <article-title>Human DNA topoisomerase I-mediated cleavage and recombination of duck hepatitis B virus DNA in vitro</article-title>. <source>Nucleic Acids Res</source>
<year>1999</year>;<volume>27</volume>:<fpage>1919</fpage>&#x02013;<lpage>25</lpage>.<pub-id pub-id-type="pmid">10101202</pub-id></mixed-citation></ref><ref id="R16"><label>16.</label><mixed-citation publication-type="journal"><name><surname>Pourquier</surname><given-names>P</given-names></name>, <name><surname>Ueng</surname><given-names>LM</given-names></name>, <name><surname>Kohlhagen</surname><given-names>G</given-names></name>, <name><surname>Mazumder</surname><given-names>A</given-names></name>, <name><surname>Gupta</surname><given-names>M</given-names></name>, <etal/>
<article-title>Effects of uracil incorporation, DNA mismatches, and abasic sites on cleavage and religation activities of mammalian topoisomerase I</article-title>. <source>J Biol Chem</source>
<year>1997</year>;<volume>272</volume>:<fpage>7792</fpage>&#x02013;<lpage>6</lpage>.<pub-id pub-id-type="pmid">9065442</pub-id></mixed-citation></ref><ref id="R17"><label>17.</label><mixed-citation publication-type="journal"><name><surname>Pourquier</surname><given-names>P</given-names></name>, <name><surname>Pilon</surname><given-names>AA</given-names></name>, <name><surname>Kohlhagen</surname><given-names>G</given-names></name>, <name><surname>Mazumder</surname><given-names>A</given-names></name>, <name><surname>Sharma</surname><given-names>A</given-names></name>, <etal/>
<article-title>Trapping of mammalian topoisomerase I and recombinations induced by damaged DNA containing nicks or gaps. Importance of DNA end phosphorylation and camptothecin effects</article-title>. <source>J Biol Chem</source>
<year>1997</year>;<volume>272</volume>:<fpage>26441</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="pmid">9334220</pub-id></mixed-citation></ref><ref id="R18"><label>18.</label><mixed-citation publication-type="journal"><name><surname>Yeh</surname><given-names>YC</given-names></name>, <name><surname>Liu</surname><given-names>HF</given-names></name>, <name><surname>Ellis</surname><given-names>CA</given-names></name>, <name><surname>Lu</surname><given-names>AL</given-names></name>. <article-title>Mammalian topoisomerase I has base mismatch nicking activity</article-title>. <source>J Biol Chem</source>
<year>1994</year>;<volume>269</volume>:<fpage>15498</fpage>&#x02013;<lpage>504</lpage>.<pub-id pub-id-type="pmid">8195193</pub-id></mixed-citation></ref><ref id="R19"><label>19.</label><mixed-citation publication-type="journal"><name><surname>Pommier</surname><given-names>Y</given-names></name>, <name><surname>Kohlhagen</surname><given-names>G</given-names></name>, <name><surname>Pourquier</surname><given-names>P</given-names></name>, <name><surname>Sayer</surname><given-names>JM</given-names></name>, <name><surname>Kroth</surname><given-names>H</given-names></name>, <etal/>
<article-title>Benzo[a]pyrene diol epoxide adducts in DNA are potent suppressors of a normal topoisomerase I cleavage site and powerful inducers of other topoisomerase I cleavages</article-title>. <source>Proc Natl Acad Sci U S A</source>
<year>2000</year>;<volume>97</volume>:<fpage>2040</fpage>&#x02013;<lpage>5</lpage>.<pub-id pub-id-type="pmid">10688881</pub-id></mixed-citation></ref><ref id="R20"><label>20.</label><mixed-citation publication-type="journal"><name><surname>Antony</surname><given-names>S</given-names></name>, <name><surname>Theruvathu</surname><given-names>JA</given-names></name>, <name><surname>Brooks</surname><given-names>PJ</given-names></name>, <name><surname>Lesher</surname><given-names>DT</given-names></name>, <name><surname>Redinbo</surname><given-names>M</given-names></name>, <etal/>
<article-title>Enhancement of camptothecin-induced topoisomerase I cleavage complexes by the acetaldehyde adduct N2-ethyl-2&#x02019;-deoxyguanosine</article-title>. <source>Nucleic Acids Res</source>
<year>2004</year>;<volume>32</volume>:<fpage>5685</fpage>&#x02013;<lpage>92</lpage>.<pub-id pub-id-type="pmid">15498925</pub-id></mixed-citation></ref><ref id="R21"><label>21.</label><mixed-citation publication-type="journal"><name><surname>Lesher</surname><given-names>DT</given-names></name>, <name><surname>Pommier</surname><given-names>Y</given-names></name>, <name><surname>Stewart</surname><given-names>L</given-names></name>, <name><surname>Redinbo</surname><given-names>MR</given-names></name>. <article-title>8-Oxoguanine rearranges the active site of human topoisomerase I</article-title>. <source>Proc Natl Acad Sci U S A</source>
<year>2002</year>;<volume>99</volume>:<fpage>12102</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="pmid">12209008</pub-id></mixed-citation></ref><ref id="R22"><label>22.</label><mixed-citation publication-type="journal"><name><surname>Galmarini</surname><given-names>CM</given-names></name>, <name><surname>Mackey</surname><given-names>JR</given-names></name>, <name><surname>Dumontet</surname><given-names>C</given-names></name>. <article-title>Nucleoside analogues and nucleobases in cancer treatment</article-title>. <source>Lancet Oncol</source>
<year>2002</year>;<volume>3</volume>:<fpage>415</fpage>&#x02013;<lpage>24</lpage>.<pub-id pub-id-type="pmid">12142171</pub-id></mixed-citation></ref><ref id="R23"><label>23.</label><mixed-citation publication-type="journal"><name><surname>Gmeiner</surname><given-names>WH</given-names></name>, <name><surname>Konerding</surname><given-names>D</given-names></name>, <name><surname>James</surname><given-names>TL</given-names></name>. <article-title>Effect of cytarabine on the NMR structure of a model okazaki fragment from the SV40 genome</article-title>. <source>Biochemistry</source>
<year>1999</year>;<volume>38</volume>:<fpage>1166</fpage>&#x02013;<lpage>75</lpage>.<pub-id pub-id-type="pmid">9930976</pub-id></mixed-citation></ref><ref id="R24"><label>24.</label><mixed-citation publication-type="journal"><name><surname>Gmeiner</surname><given-names>WH</given-names></name>, <name><surname>Skradis</surname><given-names>A</given-names></name>, <name><surname>Pon</surname><given-names>RT</given-names></name>, <name><surname>Liu</surname><given-names>J</given-names></name>. <article-title>Cytarabine-induced destabilization of a model Okazaki fragment</article-title>. <source>Nucleic Acids Res</source>
<year>1998</year>;<volume>26</volume>:<fpage>2359</fpage>&#x02013;<lpage>65</lpage>.<pub-id pub-id-type="pmid">9580686</pub-id></mixed-citation></ref><ref id="R25"><label>25.</label><mixed-citation publication-type="journal"><name><surname>Huang</surname><given-names>SY</given-names></name>, <name><surname>Murai</surname><given-names>J</given-names></name>, <name><surname>Dalla Rosa</surname><given-names>I</given-names></name>, <name><surname>Dexheimer</surname><given-names>TS</given-names></name>, <name><surname>Naumova</surname><given-names>A</given-names></name>, <etal/>
<article-title>TDP1 repairs nuclear and mitochondrial DNA damage induced by chain-terminating anticancer and antiviral nucleoside analogs</article-title>. <source>Nucleic Acids Res</source>
<year>2013</year>;<volume>41</volume>:<fpage>7793</fpage>&#x02013;<lpage>803</lpage>.<pub-id pub-id-type="pmid">23775789</pub-id></mixed-citation></ref><ref id="R26"><label>26.</label><mixed-citation publication-type="journal"><name><surname>Bonven</surname><given-names>BJ</given-names></name>, <name><surname>Gocke</surname><given-names>E</given-names></name>, <name><surname>Westergaard</surname><given-names>O</given-names></name>. <article-title>A high affinity topoisomerase I binding sequence is clustered at DNAase I hypersensitive sites in Tetrahymena R-chromatin</article-title>. <source>Cell</source>
<year>1985</year>;<volume>41</volume>:<fpage>541</fpage>&#x02013;<lpage>51</lpage>.<pub-id pub-id-type="pmid">2985282</pub-id></mixed-citation></ref><ref id="R27"><label>27.</label><mixed-citation publication-type="journal"><name><surname>Pourquier</surname><given-names>P</given-names></name>, <name><surname>Takebayashi</surname><given-names>Y</given-names></name>, <name><surname>Urasaki</surname><given-names>Y</given-names></name>, <name><surname>Gioffre</surname><given-names>C</given-names></name>, <name><surname>Kohlhagen</surname><given-names>G</given-names></name>, <etal/>
<article-title>Induction of topoisomerase I cleavage complexes by 1-beta-D-arabinofuranosylcytosine (ara-C) in vitro and in ara-C-treated cells</article-title>. <source>Proc Natl Acad Sci U S A</source>
<year>2000</year>;<volume>97</volume>:<fpage>1885</fpage>&#x02013;<lpage>90</lpage>.<pub-id pub-id-type="pmid">10677551</pub-id></mixed-citation></ref><ref id="R28"><label>28.</label><mixed-citation publication-type="journal"><name><surname>Patel</surname><given-names>AG</given-names></name>, <name><surname>Flatten</surname><given-names>KS</given-names></name>, <name><surname>Peterson</surname><given-names>KL</given-names></name>, <name><surname>Beito</surname><given-names>TG</given-names></name>, <name><surname>Schneider</surname><given-names>PA</given-names></name>, <etal/>
<article-title>Immunodetection of human topoisomerase I-DNA covalent complexes</article-title>. <source>Nucleic Acids Res</source>
<year>2016</year>;<volume>44</volume>:<fpage>2816</fpage>&#x02013;<lpage>26</lpage>.<pub-id pub-id-type="pmid">26917015</pub-id></mixed-citation></ref><ref id="R29"><label>29.</label><mixed-citation publication-type="journal"><name><surname>Cline</surname><given-names>SD</given-names></name>, <name><surname>Osheroff</surname><given-names>N</given-names></name>. <article-title>Cytosine arabinoside lesions are position-specific topoisomerase II poisons and stimulate DNA cleavage mediated by the human type II enzymes</article-title>. <source>J Biol Chem</source>
<year>1999</year>;<volume>274</volume>:<fpage>29740</fpage>&#x02013;<lpage>3</lpage>.<pub-id pub-id-type="pmid">10514448</pub-id></mixed-citation></ref><ref id="R30"><label>30.</label><mixed-citation publication-type="journal"><name><surname>Loegering</surname><given-names>D</given-names></name>, <name><surname>Arlander</surname><given-names>SJ</given-names></name>, <name><surname>Hackbarth</surname><given-names>J</given-names></name>, <name><surname>Vroman</surname><given-names>BT</given-names></name>, <name><surname>Roos-Mattjus</surname><given-names>P</given-names></name>, <etal/>
<article-title>Rad9 protects cells from topoisomerase poison-induced cell death</article-title>. <source>J Biol Chem</source>
<year>2004</year>;<volume>279</volume>:<fpage>18641</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="pmid">14988409</pub-id></mixed-citation></ref><ref id="R31"><label>31.</label><mixed-citation publication-type="journal"><name><surname>Sousa</surname><given-names>FG</given-names></name>, <name><surname>Matuo</surname><given-names>R</given-names></name>, <name><surname>Tang</surname><given-names>SW</given-names></name>, <name><surname>Rajapakse</surname><given-names>VN</given-names></name>, <name><surname>Luna</surname><given-names>A</given-names></name>, <etal/>
<article-title>Alterations of DNA repair genes in the NCI-60 cell lines and their predictive value for anticancer drug activity</article-title>. <source>DNA Repair (Amst)</source>
<year>2015</year>;<volume>28</volume>:<fpage>107</fpage>&#x02013;<lpage>15</lpage>.<pub-id pub-id-type="pmid">25758781</pub-id></mixed-citation></ref><ref id="R32"><label>32.</label><mixed-citation publication-type="journal"><name><surname>Zoppoli</surname><given-names>G</given-names></name>, <name><surname>Regairaz</surname><given-names>M</given-names></name>, <name><surname>Leo</surname><given-names>E</given-names></name>, <name><surname>Reinhold</surname><given-names>WC</given-names></name>, <name><surname>Varma</surname><given-names>S</given-names></name>, <etal/>
<article-title>Putative DNA/RNA helicase Schlafen-11 (SLFN11) sensitizes cancer cells to DNA-damaging agents</article-title>. <source>Proc Natl Acad Sci U S A</source>
<year>2012</year>;<volume>109</volume>:<fpage>15030</fpage>&#x02013;<lpage>5</lpage>.<pub-id pub-id-type="pmid">22927417</pub-id></mixed-citation></ref><ref id="R33"><label>33.</label><mixed-citation publication-type="journal"><name><surname>Murai</surname><given-names>J</given-names></name>, <name><surname>Tang</surname><given-names>SW</given-names></name>, <name><surname>Leo</surname><given-names>E</given-names></name>, <name><surname>Baechler</surname><given-names>SA</given-names></name>, <name><surname>Redon</surname><given-names>CE</given-names></name>, <etal/>
<article-title>SLFN11 Blocks Stressed Replication Forks Independently of ATR</article-title>. <source>Mol Cell</source>
<year>2018</year>;<volume>69</volume>:<fpage>371</fpage>&#x02013;<lpage>84.e6</lpage>.<pub-id pub-id-type="pmid">29395061</pub-id></mixed-citation></ref><ref id="R34"><label>34.</label><mixed-citation publication-type="journal"><name><surname>Al Abo</surname><given-names>M</given-names></name>, <name><surname>Sasanuma</surname><given-names>H</given-names></name>, <name><surname>Liu</surname><given-names>X</given-names></name>, <name><surname>Rajapakse</surname><given-names>VN</given-names></name>, <name><surname>Huang</surname><given-names>SY</given-names></name>, <etal/>
<article-title>TDP1 is critical for the repair of DNA breaks induced by sapacitabine, a nucleoside also targeting ATM- and BRCA-deficient tumors</article-title>. <source>Mol Cancer Ther</source>
<year>2017</year>;<volume>16</volume>:<fpage>2543</fpage>&#x02013;<lpage>51</lpage>.<pub-id pub-id-type="pmid">28802254</pub-id></mixed-citation></ref><ref id="R35"><label>35.</label><mixed-citation publication-type="journal"><name><surname>Mini</surname><given-names>E</given-names></name>, <name><surname>Nobili</surname><given-names>S</given-names></name>, <name><surname>Caciagli</surname><given-names>B</given-names></name>, <name><surname>Landini</surname><given-names>I</given-names></name>, <name><surname>Mazzei</surname><given-names>T</given-names></name>. <article-title>Cellular pharmacology of gemcitabine</article-title>. <source>Ann Oncol</source>
<year>2006</year>;<volume>17</volume>
<issue>Suppl 5</issue>:<fpage>v7</fpage>&#x02013;<lpage>12</lpage>.<pub-id pub-id-type="pmid">16807468</pub-id></mixed-citation></ref><ref id="R36"><label>36.</label><mixed-citation publication-type="journal"><name><surname>Huang</surname><given-names>P</given-names></name>, <name><surname>Chubb</surname><given-names>S</given-names></name>, <name><surname>Hertel</surname><given-names>LW</given-names></name>, <name><surname>Grindey</surname><given-names>GB</given-names></name>, <name><surname>Plunkett</surname><given-names>W</given-names></name>. <article-title>Action of 2&#x02019;,2&#x02019;-difluorodeoxycytidine on DNA synthesis</article-title>. <source>Cancer Res</source>
<year>1991</year>;<volume>51</volume>:<fpage>6110</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="pmid">1718594</pub-id></mixed-citation></ref><ref id="R37"><label>37.</label><mixed-citation publication-type="journal"><name><surname>Konerding</surname><given-names>D</given-names></name>, <name><surname>James</surname><given-names>TL</given-names></name>, <name><surname>Trump</surname><given-names>E</given-names></name>, <name><surname>Soto</surname><given-names>AM</given-names></name>, <name><surname>Marky</surname><given-names>LA</given-names></name>, <etal/>
<article-title>NMR structure of a gemcitabine-substituted model Okazaki fragment</article-title>. <source>Biochemistry</source>
<year>2002</year>;<volume>41</volume>:<fpage>839</fpage>&#x02013;<lpage>46</lpage>.<pub-id pub-id-type="pmid">11790105</pub-id></mixed-citation></ref><ref id="R38"><label>38.</label><mixed-citation publication-type="journal"><name><surname>Gmeiner</surname><given-names>WH</given-names></name>. <article-title>Antimetabolite incorporation into DNA: structural and thermodynamic basis for anticancer activity</article-title>. <source>Biopolymers</source>
<year>2002</year>;<volume>65</volume>:<fpage>180</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">12228923</pub-id></mixed-citation></ref><ref id="R39"><label>39.</label><mixed-citation publication-type="journal"><name><surname>Pourquier</surname><given-names>P</given-names></name>, <name><surname>Gioffre</surname><given-names>C</given-names></name>, <name><surname>Kohlhagen</surname><given-names>G</given-names></name>, <name><surname>Urasaki</surname><given-names>Y</given-names></name>, <name><surname>Goldwasser</surname><given-names>F</given-names></name>, <etal/>
<article-title>Gemcitabine (2&#x02019;,2&#x02019;-difluoro-2&#x02019;-deoxycytidine), an antimetabolite that poisons topoisomerase I</article-title>. <source>Clin Cancer Res</source>
<year>2002</year>;<volume>8</volume>:<fpage>2499</fpage>&#x02013;<lpage>504</lpage>.<pub-id pub-id-type="pmid">12171875</pub-id></mixed-citation></ref><ref id="R40"><label>40.</label><mixed-citation publication-type="journal"><name><surname>An</surname><given-names>Q</given-names></name>, <name><surname>Robins</surname><given-names>P</given-names></name>, <name><surname>Lindahl</surname><given-names>T</given-names></name>, <name><surname>Barnes</surname><given-names>DE</given-names></name>. <article-title>5-Fluorouracil incorporated into DNA is excised by the Smug1 DNA glycosylase to reduce drug cytotoxicity</article-title>. <source>Cancer Res</source>
<year>2007</year>;<volume>67</volume>:<fpage>940</fpage>&#x02013;<lpage>5</lpage>.<pub-id pub-id-type="pmid">17283124</pub-id></mixed-citation></ref><ref id="R41"><label>41.</label><mixed-citation publication-type="journal"><name><surname>Ensminger</surname><given-names>WD</given-names></name>, <name><surname>Rosowsky</surname><given-names>A</given-names></name>, <name><surname>Raso</surname><given-names>V</given-names></name>, <name><surname>Levin</surname><given-names>DC</given-names></name>, <name><surname>Glode</surname><given-names>M</given-names></name>, <etal/>
<article-title>A clinical-pharmacological evaluation of hepatic arterial infusions of 5-fluoro-2&#x02019;-deoxyuridine and 5-fluorouracil</article-title>. <source>Cancer Res</source>
<year>1978</year>;<volume>38</volume>:<fpage>3784</fpage>&#x02013;<lpage>92</lpage>.<pub-id pub-id-type="pmid">151583</pub-id></mixed-citation></ref><ref id="R42"><label>42.</label><mixed-citation publication-type="journal"><name><surname>Gmeiner</surname><given-names>WH</given-names></name>. <article-title>Novel chemical strategies for thymidylate synthase inhibition</article-title>. <source>Curr Med Chem</source>
<year>2005</year>;<volume>12</volume>:<fpage>191</fpage>&#x02013;<lpage>202</lpage>.<pub-id pub-id-type="pmid">15638735</pub-id></mixed-citation></ref><ref id="R43"><label>43.</label><mixed-citation publication-type="journal"><name><surname>Saif</surname><given-names>MW</given-names></name>, <name><surname>Syrigos</surname><given-names>K</given-names></name>, <name><surname>Mehra</surname><given-names>R</given-names></name>, <name><surname>Mattison</surname><given-names>LK</given-names></name>, <name><surname>Diasio</surname><given-names>RB</given-names></name>. <article-title>Dihydropyrimidine dehydrogenase deficiency (Dpd) in Gi malignancies: experience of 4-years</article-title>. <source>Pak J Med Sci</source>
<year>2007</year>;<volume>23</volume>:<fpage>832</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">18846242</pub-id></mixed-citation></ref><ref id="R44"><label>44.</label><mixed-citation publication-type="journal"><name><surname>Dominijanni</surname><given-names>A</given-names></name>, <name><surname>Gmeiner</surname><given-names>WH</given-names></name>. <article-title>Improved potency of F10 relative to 5-fluorouracil in colorectal cancer cells with p53 mutations</article-title>. <source>Cancer Drug Resist</source>
<year>2018</year>;<volume>1</volume>:<fpage>48</fpage>&#x02013;<lpage>58</lpage>.<pub-id pub-id-type="pmid">30613833</pub-id></mixed-citation></ref><ref id="R45"><label>45.</label><mixed-citation publication-type="journal"><name><surname>Gmeiner</surname><given-names>WH</given-names></name>, <name><surname>Debinski</surname><given-names>W</given-names></name>, <name><surname>Milligan</surname><given-names>C</given-names></name>, <name><surname>Caudell</surname><given-names>D</given-names></name>, <name><surname>Pardee</surname><given-names>TS</given-names></name>. <article-title>The applications of the novel polymeric fluoropyrimidine F10 in cancer treatment: current evidence</article-title>. <source>Future Oncol</source>
<year>2016</year>;<volume>12</volume>:<fpage>2009</fpage>&#x02013;<lpage>20</lpage>.<pub-id pub-id-type="pmid">27279153</pub-id></mixed-citation></ref><ref id="R46"><label>46.</label><mixed-citation publication-type="journal"><name><surname>Liao</surname><given-names>ZY</given-names></name>, <name><surname>Sordet</surname><given-names>O</given-names></name>, <name><surname>Zhang</surname><given-names>HL</given-names></name>, <name><surname>Kohlhagen</surname><given-names>G</given-names></name>, <name><surname>Antony</surname><given-names>S</given-names></name>, <etal/>
<article-title>A novel polypyrimidine antitumor agent FdUMP[10] induces thymineless death with topoisomerase I-DNA complexes</article-title>. <source>Cancer Res</source>
<year>2005</year>;<volume>65</volume>:<fpage>4844</fpage>&#x02013;<lpage>51</lpage>.<pub-id pub-id-type="pmid">15930305</pub-id></mixed-citation></ref><ref id="R47"><label>47.</label><mixed-citation publication-type="journal"><name><surname>Gmeiner</surname><given-names>WH</given-names></name>, <name><surname>Reinhold</surname><given-names>WC</given-names></name>, <name><surname>Pommier</surname><given-names>Y</given-names></name>. <article-title>Genome-wide mRNA and microRNA profiling of the NCI 60 cell-line screen and comparison of FdUMP[10] with fluorouracil, floxuridine, and topoisomerase 1 poisons</article-title>. <source>Mol Cancer Ther</source>
<year>2010</year>;<volume>9</volume>:<fpage>3105</fpage>&#x02013;<lpage>14</lpage>.<pub-id pub-id-type="pmid">21159603</pub-id></mixed-citation></ref><ref id="R48"><label>48.</label><mixed-citation publication-type="journal"><name><surname>Pardee</surname><given-names>TS</given-names></name>, <name><surname>Stadelman</surname><given-names>K</given-names></name>, <name><surname>Jennings-Gee</surname><given-names>J</given-names></name>, <name><surname>Caudell</surname><given-names>DL</given-names></name>, <name><surname>Gmeiner</surname><given-names>WH</given-names></name>. <article-title>The poison oligonucleotide F10 is highly effective against acute lymphoblastic leukemia while sparing normal hematopoietic cells</article-title>. <source>Oncotarget</source>
<year>2014</year>;<volume>5</volume>:<fpage>4170</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">24961587</pub-id></mixed-citation></ref><ref id="R49"><label>49.</label><mixed-citation publication-type="journal"><name><surname>Holbeck</surname><given-names>SL</given-names></name>, <name><surname>Collins</surname><given-names>JM</given-names></name>, <name><surname>Doroshow</surname><given-names>JH</given-names></name>. <article-title>Analysis of Food and Drug Administration-approved anticancer agents in the NCI60 panel of human tumor cell lines</article-title>. <source>Mol Cancer Ther</source>
<year>2010</year>;<volume>9</volume>:<fpage>1451</fpage>&#x02013;<lpage>60</lpage>.<pub-id pub-id-type="pmid">20442306</pub-id></mixed-citation></ref><ref id="R50"><label>50.</label><mixed-citation publication-type="journal"><name><surname>Gmeiner</surname><given-names>WH</given-names></name>, <name><surname>Yu</surname><given-names>S</given-names></name>, <name><surname>Pon</surname><given-names>RT</given-names></name>, <name><surname>Pourquier</surname><given-names>P</given-names></name>, <name><surname>Pommier</surname><given-names>Y</given-names></name>. <article-title>Structural basis for topoisomerase I inhibition by nucleoside analogs</article-title>. <source>Nucleosides Nucleotides Nucleic Acids</source>
<year>2003</year>;<volume>22</volume>:<fpage>653</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">14565246</pub-id></mixed-citation></ref><ref id="R51"><label>51.</label><mixed-citation publication-type="journal"><name><surname>Gmeiner</surname><given-names>WH</given-names></name>, <name><surname>Salsbury</surname><given-names>F</given-names><suffix>Jr</suffix></name>, <name><surname>Olsen</surname><given-names>CM</given-names></name>, <name><surname>Marky</surname><given-names>LA</given-names></name>. <article-title>The stability of a model substrate for topoisomerase 1-mediated DNA religation depends on the presence of mismatched base pairs</article-title>. <source>J Nucleic Acids</source>
<year>2011</year>;<volume>2011</volume>:<fpage>631372</fpage>.<pub-id pub-id-type="pmid">21904666</pub-id></mixed-citation></ref><ref id="R52"><label>52.</label><mixed-citation publication-type="journal"><name><surname>Jennings-Gee</surname><given-names>J</given-names></name>, <name><surname>Pardee</surname><given-names>TS</given-names></name>, <name><surname>Gmeiner</surname><given-names>WH</given-names></name>. <article-title>Replication-dependent irreversible topoisomerase 1 poisoning is responsible for FdUMP[10] anti-leukemic activity</article-title>. <source>Exp Hematol</source>
<year>2013</year>;<volume>41</volume>:<fpage>180</fpage>&#x02013;<lpage>8.e4</lpage>.<pub-id pub-id-type="pmid">23085462</pub-id></mixed-citation></ref><ref id="R53"><label>53.</label><mixed-citation publication-type="journal"><name><surname>Gmeiner</surname><given-names>WH</given-names></name>, <name><surname>Gearhart</surname><given-names>PJ</given-names></name>, <name><surname>Pommier</surname><given-names>Y</given-names></name>, <name><surname>Nakamura</surname><given-names>J</given-names></name>. <article-title>F10 cytotoxicity via topoisomerase I cleavage complex repair consistent with a unique mechanism for thymineless death</article-title>. <source>Future Oncol</source>
<year>2016</year>;<volume>12</volume>:<fpage>2183</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">27333295</pub-id></mixed-citation></ref><ref id="R54"><label>54.</label><mixed-citation publication-type="journal"><name><surname>Das</surname><given-names>BB</given-names></name>, <name><surname>Huang</surname><given-names>SY</given-names></name>, <name><surname>Murai</surname><given-names>J</given-names></name>, <name><surname>Rehman</surname><given-names>I</given-names></name>, <name><surname>Ame</surname><given-names>JC</given-names></name>, <etal/>
<article-title>PARP1-TDP1 coupling for the repair of topoisomerase I-induced DNA damage</article-title>. <source>Nucleic Acids Res</source>
<year>2014</year>;<volume>42</volume>:<fpage>4435</fpage>&#x02013;<lpage>49</lpage>.<pub-id pub-id-type="pmid">24493735</pub-id></mixed-citation></ref><ref id="R55"><label>55.</label><mixed-citation publication-type="journal"><name><surname>Pardee</surname><given-names>TS</given-names></name>, <name><surname>Gomes</surname><given-names>E</given-names></name>, <name><surname>Jennings-Gee</surname><given-names>J</given-names></name>, <name><surname>Caudell</surname><given-names>D</given-names></name>, <name><surname>Gmeiner</surname><given-names>WH</given-names></name>. <article-title>Unique dual targeting of thymidylate synthase and topoisomerase1 by FdUMP[10] results in high efficacy against AML and low toxicity</article-title>. <source>Blood</source>
<year>2012</year>;<volume>119</volume>:<fpage>3561</fpage>&#x02013;<lpage>70</lpage>.<pub-id pub-id-type="pmid">22362039</pub-id></mixed-citation></ref><ref id="R56"><label>56.</label><mixed-citation publication-type="journal"><name><surname>Gmeiner</surname><given-names>WH</given-names></name>, <name><surname>Willingham</surname><given-names>MC</given-names></name>, <name><surname>Bourland</surname><given-names>JD</given-names></name>, <name><surname>Hatcher</surname><given-names>HC</given-names></name>, <name><surname>Smith</surname><given-names>TL</given-names></name>, <etal/>
<article-title>F10 inhibits growth of PC3 xenografts and enhances the effects of radiation therapy</article-title>. <source>J Clin Oncol Res</source>
<year>2014</year>;<volume>2</volume>:pii:<fpage>1028</fpage>.<pub-id pub-id-type="pmid">26020060</pub-id></mixed-citation></ref><ref id="R57"><label>57.</label><mixed-citation publication-type="journal"><name><surname>Gmeiner</surname><given-names>WH</given-names></name>, <name><surname>Lema-Tome</surname><given-names>C</given-names></name>, <name><surname>Gibo</surname><given-names>D</given-names></name>, <name><surname>Jennings-Gee</surname><given-names>J</given-names></name>, <name><surname>Milligan</surname><given-names>C</given-names></name>, <etal/>
<article-title>Selective anti-tumor activity of the novel fluoropyrimidine polymer F10 towards G48a orthotopic GBM tumors</article-title>. <source>J Neurooncol</source>
<year>2014</year>;<volume>116</volume>:<fpage>447</fpage>&#x02013;<lpage>54</lpage>.<pub-id pub-id-type="pmid">24346635</pub-id></mixed-citation></ref><ref id="R58"><label>58.</label><mixed-citation publication-type="journal"><name><surname>Wahner Hendrickson</surname><given-names>AE</given-names></name>, <name><surname>Menefee</surname><given-names>ME</given-names></name>, <name><surname>Hartmann</surname><given-names>LC</given-names></name>, <name><surname>Long</surname><given-names>HJ</given-names></name>, <name><surname>Northfelt</surname><given-names>DW</given-names></name>, <etal/>
<article-title>A phase I clinical trial of the Poly(ADP-ribose) polymerase inhibitor veliparib and weekly topotecan in patients with solid tumors</article-title>. <source>Clin Cancer Res</source>
<year>2018</year>;<volume>24</volume>:<fpage>744</fpage>&#x02013;<lpage>52</lpage>.<pub-id pub-id-type="pmid">29138343</pub-id></mixed-citation></ref><ref id="R59"><label>59.</label><mixed-citation publication-type="journal"><name><surname>Murai</surname><given-names>J</given-names></name>, <name><surname>Thomas</surname><given-names>A</given-names></name>, <name><surname>Miettinen</surname><given-names>M</given-names></name>, <name><surname>Pommier</surname><given-names>Y</given-names></name>. <article-title>Schlafen 11 (SLFN11), a restriction factor for replicative stress induced by DNA-targeting anti-cancer therapies</article-title>. <source>Pharmacol Ther</source>
<year>2019</year>;<volume>201</volume>:<fpage>94</fpage>&#x02013;<lpage>102</lpage>.<pub-id pub-id-type="pmid">31128155</pub-id></mixed-citation></ref></ref-list></back><floats-group><fig id="F1" orientation="portrait" position="float"><label>Figure 1.</label><caption><p id="P22">Substitution of nucleoside analogs into a model Top1 cleavage site results in Top1cc. (Top) The chemical structures for three nucleoside analogs that induce Top1cc in genomic DNA; (Middle) sequence of a model Top1cc used to investigate nucleoside analog substitution effects on Top1cc with the +1 site in the non-scissile strand highlighted; and (Bottom) 23mer model Top1cc substrate used to study cleavage/re-ligation effects of nucleoside analogs. *A corresponds to the [<sup>32</sup>P]-cordycepin label. Modified from References<sup>[<xref rid="R27" ref-type="bibr">27</xref>,<xref rid="R39" ref-type="bibr">39</xref>,<xref rid="R46" ref-type="bibr">46</xref>]</sup>. Top1: topoisomerase 1; AraC: cytarabine; GEM: gemcitabine; FdU: 5-fluoro-2&#x02019;-deoxyuridine; Top1cc: Top1 cleavage complex</p></caption><graphic xlink:href="nihms-1063588-f0001"/></fig><fig id="F2" orientation="portrait" position="float"><label>Figure 2.</label><caption><p id="P23">F10 and CPTs both form Top1cc but have different outcomes in response to PARP1/TDP1-mediated repair. A: CPTs form ternary Top1cc that are repaired thru proteasomal degradation to a peptide stub, TDP1-mediated cleavage of the peptide: DNA bond, and PNKP-mediated modulation of 5&#x02032;-end-phosphorylation status followed by ligation to restore the duplex. In contrast, this same enzymatic process retains FdU in DNA and is susceptible to further Top1cc formation at the same site; B: Activation of homologous HRR due to incomplete TDP1-mediated repair stimulates DNA resection and re-synthesis, which under thymineless conditions increases FdUTP incorporation into DNA, stimulating further Top1-mediated DNA damage; C: In DT40 cells, F10 and CPTs display opposite dependence on TDP1 and PARP1 expression<sup>[<xref rid="R53" ref-type="bibr">53</xref>]</sup>. CPT: camptothecin; Top1: topoisomerase 1; HRR: recombination repair; TDP1: tyrosyl DNA phosphodiesterase 1; TS: thymidylate synthase; Top1cc: Top1 cleavage complex</p></caption><graphic xlink:href="nihms-1063588-f0002"/></fig><table-wrap id="T1" position="float" orientation="portrait"><label>Table 1.</label><caption><p id="P24">Summary of nucleoside analogs and other DNA damage effects on Top1cc</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" valign="top" rowspan="1" colspan="1">Substitution</th><th align="center" valign="top" rowspan="1" colspan="1">Effects on Top1cc</th><th align="center" valign="top" rowspan="1" colspan="1">Ref.</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Abasic site</td><td align="left" valign="top" rowspan="1" colspan="1">Position-dependent, stable Top1cc in absence of CPT or suppression of Top1 cleavage</td><td align="left" valign="top" rowspan="1" colspan="1">[<xref rid="R16" ref-type="bibr">16</xref>,<xref rid="R17" ref-type="bibr">17</xref>]</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">8-Oxo-dG</td><td align="left" valign="top" rowspan="1" colspan="1">Position-dependent effects +1 scissile strand stabilized inactive Top1</td><td align="left" valign="top" rowspan="1" colspan="1">[<xref rid="R13" ref-type="bibr">13</xref>,<xref rid="R21" ref-type="bibr">21</xref>]</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">BaP</td><td align="left" valign="top" rowspan="1" colspan="1">Position-dependent effects</td><td align="left" valign="top" rowspan="1" colspan="1">[<xref rid="R19" ref-type="bibr">19</xref>]</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">AraC</td><td align="left" valign="top" rowspan="1" colspan="1">AraC in either scissile or non-scissile strand enhanced Top1cc; CPT-resistant cells are cross-resistant to AraC</td><td align="left" valign="top" rowspan="1" colspan="1">[<xref rid="R27" ref-type="bibr">27</xref>]</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">GEM</td><td align="left" valign="top" rowspan="1" colspan="1">Position-dependent effects including inducing new Top1cc sites; CPT-resistant cells are cross-resistant to GEM</td><td align="left" valign="top" rowspan="1" colspan="1">[<xref rid="R39" ref-type="bibr">39</xref>]</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">FdU</td><td align="left" valign="top" rowspan="1" colspan="1">FdU substitution +1 or +2 in non-scissile strand inhibited re-ligation step of Top1 catalysis; Top1cc important for F10 biological activity; opposite effect of Tdp1 knockout relative to CPT</td><td align="left" valign="top" rowspan="1" colspan="1">[<xref rid="R46" ref-type="bibr">46</xref>,<xref rid="R48" ref-type="bibr">48</xref>,<xref rid="R52" ref-type="bibr">52</xref>,<xref rid="R53" ref-type="bibr">53</xref>,<xref rid="R55" ref-type="bibr">55</xref>,<xref rid="R57" ref-type="bibr">57</xref>]</td></tr></tbody></table><table-wrap-foot><fn id="TFN1"><p id="P25">CPT: camptothecin; Top1: topoisomerase 1; AraC: cytarabine; GEM: gemcitabine; FdU: 5-fluoro-2&#x02032;-deoxyuridine; Tdp1: tyrosyl DNA phosphodiesterase 1; Top1cc: Top1 cleavage complex</p></fn></table-wrap-foot></table-wrap></floats-group></article>